332 related articles for article (PubMed ID: 31789693)
1. Weight gain and integrase inhibitors.
Eckard AR; McComsey GA
Curr Opin Infect Dis; 2020 Feb; 33(1):10-19. PubMed ID: 31789693
[TBL] [Abstract][Full Text] [Related]
2. Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada.
Bourgi K; Jenkins CA; Rebeiro PF; Palella F; Moore RD; Altoff KN; Gill J; Rabkin CS; Gange SJ; Horberg MA; Margolick J; Li J; Wong C; Willig A; Lima VD; Crane H; Thorne J; Silverberg M; Kirk G; Mathews WC; Sterling TR; Lake J; Koethe JR;
J Int AIDS Soc; 2020 Apr; 23(4):e25484. PubMed ID: 32294337
[TBL] [Abstract][Full Text] [Related]
3. Increase in visceral adipose tissue in a woman living with HIV after introduction of integrase strand transfer inhibitor.
Piacentini D; Lanzafame M; Rizzardo S; Chiesi S; Lattuada E; Mehrabi S; Zamboni G; Mazzi R; Tacconelli E; Vento S
Int J STD AIDS; 2020 Dec; 31(14):1407-1410. PubMed ID: 33081650
[TBL] [Abstract][Full Text] [Related]
4. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.
Bourgi K; Rebeiro PF; Turner M; Castilho JL; Hulgan T; Raffanti SP; Koethe JR; Sterling TR
Clin Infect Dis; 2020 Mar; 70(7):1267-1274. PubMed ID: 31100116
[TBL] [Abstract][Full Text] [Related]
5. Brief Report: Integrase Strand Transfer Inhibitors Are Associated With Lower Risk of Incident Cardiovascular Disease in People Living With HIV.
O'Halloran JA; Sahrmann J; Butler AM; Olsen MA; Powderly WG
J Acquir Immune Defic Syndr; 2020 Aug; 84(4):396-399. PubMed ID: 32243280
[TBL] [Abstract][Full Text] [Related]
6. Nothing is perfect: the safety issues of integrase inhibitor regimens.
Scévola S; Tiraboschi JM; Podzamczer D
Expert Opin Drug Saf; 2020 Jun; 19(6):683-694. PubMed ID: 32356477
[TBL] [Abstract][Full Text] [Related]
7. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
8. Risks of metabolic syndrome and diabetes with integrase inhibitor-based therapy.
Shah S; Hill A
Curr Opin Infect Dis; 2021 Feb; 34(1):16-24. PubMed ID: 33278177
[TBL] [Abstract][Full Text] [Related]
9. Obesity Modifies the Relationship Between Raltegravir and Dolutegravir Hair Concentrations and Body Weight Gain in Women Living with HIV.
Lahiri CD; Mehta CC; Sykes C; Weiser SD; Palella F; Lake JE; Mellors JW; Gustafson D; French AL; Adimora AA; Konkle-Parker D; Sharma A; Bolivar H; Kassaye SG; Rubin LH; Alvarez JA; Golub ET; Ofotokun I; Sheth AN
AIDS Res Hum Retroviruses; 2023 Dec; 39(12):644-651. PubMed ID: 37140468
[TBL] [Abstract][Full Text] [Related]
10. Weight Change When Initiating, Switching to, and Discontinuing Integrase Strand Transfer Inhibitors in People Living with HIV.
Tieosapjaroen W; Chow EPF; Fairley CK; Hoy J; Aguirre I; Ong JJ
AIDS Patient Care STDS; 2023 Mar; 37(3):131-137. PubMed ID: 36809049
[TBL] [Abstract][Full Text] [Related]
11. Virologic Failure Among People Living With HIV Initiating Dolutegravir-Based Versus Other Recommended Regimens in Real-World Clinical Care Settings.
Nance RM; Vannappagari V; Smith K; Johannes CB; Calingaert B; Saltus CW; Mayer KH; Whitney BM; Rodriguez B; Moore RD; Eron JJ; Geng E; Mathews WC; Mugavero MJ; Saag MS; Kitahata MM; Delaney JAC; Crane HM
J Acquir Immune Defic Syndr; 2019 Aug; 81(5):572-577. PubMed ID: 31107299
[TBL] [Abstract][Full Text] [Related]
12. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen.
Santoro MM; Fornabaio C; Malena M; Galli L; Poli A; Menozzi M; Zazzi M; White KL; Castagna A;
Int J Antimicrob Agents; 2020 Jul; 56(1):106027. PubMed ID: 32450199
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug reactions to integrase strand transfer inhibitors.
Lepik KJ; Yip B; Ulloa AC; Wang L; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2018 Apr; 32(7):903-912. PubMed ID: 29424784
[TBL] [Abstract][Full Text] [Related]
15. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.
Burns JE; Stirrup OT; Dunn D; Runcie-Unger I; Milinkovic A; Candfield S; Lukha H; Severn A; Waters L; Edwards S; Gilson R; Pett SL
AIDS; 2020 Jan; 34(1):109-114. PubMed ID: 31567162
[TBL] [Abstract][Full Text] [Related]
16. The Integrase Inhibitors Dolutegravir and Raltegravir Exert Proadipogenic and Profibrotic Effects and Induce Insulin Resistance in Human/Simian Adipose Tissue and Human Adipocytes.
Gorwood J; Bourgeois C; Pourcher V; Pourcher G; Charlotte F; Mantecon M; Rose C; Morichon R; Atlan M; Le Grand R; Desjardins D; Katlama C; Fève B; Lambotte O; Capeau J; Béréziat V; Lagathu C
Clin Infect Dis; 2020 Dec; 71(10):e549-e560. PubMed ID: 32166319
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis and systematic review of the efficacy and resistance for human immunodeficiency virus type 1 integrase strand transfer inhibitors.
Yang LL; Li Q; Zhou LB; Chen SQ
Int J Antimicrob Agents; 2019 Nov; 54(5):547-555. PubMed ID: 31398480
[TBL] [Abstract][Full Text] [Related]
18. Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study.
Underwood M; Horton J; Nangle K; Hopking J; Smith K; Aboud M; Wynne B; Sievers J; Stewart EL; Wang R
Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164321. PubMed ID: 34694877
[TBL] [Abstract][Full Text] [Related]
19. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
[TBL] [Abstract][Full Text] [Related]
20. Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV.
Capeau J; Lagathu C; Béréziat V
Curr Opin HIV AIDS; 2024 Jan; 19(1):14-20. PubMed ID: 38078606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
